

Haemostatic therapy in spontaneous intracerebral haemorrhage patients with high-risk of haematoma expansion by CT marker: a systematic review and meta-analysis of randomised trials

Ximing Nie (1,2) Jingyi Liu (1,2) Jingyi Chang Jingyi Chang

ABSTRACT

et al. Haemostatic therapy Background and purpose Current randomised in spontaneous intracerebral controlled trials (RCTs) showed an uncertain benefit haemorrhage patients with of haemostatic therapy on preventing haematoma high-risk of haematoma expansion and improving the outcome in patients with expansion by CT marker: a intracerebral haemorrhage (ICH). This meta-analysis aims systematic review and metato systematically evaluate the effect of haemostatic agents analysis of randomised trials. Stroke & Vascular Neurology on the prevention of haemorrhage growth in patients with 2021;6: e000941. doi:10.1136/ high-risk spontaneous ICH predicted by CT signs in RCTs. svn-2021-000941 Methods A comprehensive search of PubMed, EMBASE and Cochrane library from 1 January 2005 to 30 June Additional supplemental 2021 was conducted. RCTs that compared haemostatic material is published online only. To view, please visit the journal online (http://dx.doi.org/10.

Received 15 February 2021 Revised 23 March 2021 Accepted 26 March 2021 Published Online First 1 April 2021

1136/svn-2021-000941).

To cite: Nie X, Liu J, Liu D,

Check for updates

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Professor Liping Liu; lipingsister@gmail.com





significant level when compared with placebo (OR 0.84; 95% Cl 0.70 to 1.00; p=0.051). Subgroup analysis for patients with black hole sign on CT revealed a significant reduction of haematoma expansion with haemostatic therapy (OR 0.61; 95% Cl 0.39 to 0.94; p=0.03). However, both the primary analysis and subgroup analyses showed that haemostatic therapy could not reduce the rate of poor functional outcome (modified Rankin Scale >3) or death. **Conclusions** Haemostatic therapy showed a marginally significant benefit in reducing early haematoma expansion in patients with high-risk spontaneous ICH predicted by markers on CT scan. However, no significant improvement in functional outcome or reduction of mortality was observed.

INTRODUCTION

Spontaneous intracerebral haemorrhage (ICH) is one of the devastating strokes associated with the highest mortality and disability worldwide.¹ Current surgical or medical treatment showed no clear benefit.^{2 3} Clinically, haematoma expansion is associated with early neurological deterioration and poor clinical outcome and a target of intervention.⁴⁵ Haemostatic therapy has been shown to prevent haematoma expansion in patients with spontaneous ICH but with very limited evidence.⁶ In theory, haemostatic therapy is more suitable for patients with high-risk for ICH growth, such as patients with early CT signs of haematoma expansion.⁷ For this reason, high-risk haematoma growth patients with ICH with image markers, such as the spot sign,⁸ ⁹ black hole sign¹⁰ and blend sign¹¹ on CT scan were identified as candidates for haemostatic therapy studied in several randomised trials.⁶ ^{12–14} With the recent completion of Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign (TRAIGE) trial¹² and the results of other trials using haemostatic agents, a possible consistent trend for reducing haematoma expansion was seen. On the other hand, some of these trials showed conflicting results. We, therefore, performed a meta-analysis and systematic review of the available evidence to evaluate the effect of haemostatic agents on the prevention of haemorrhage growth in patients with high-risk spontaneous ICH predicted by positive signs on CT (spot sign, blend sign or black hole sign).

METHODS

Search strategy

The Preferred Reporting Items for Systematic reviews and Meta-Analyses statement for reporting systematic reviews and metaanalyses of randomised controlled trials (RCTs) were followed in this meta-analysis.¹⁵ PubMed, EMBASE and Cochrane library were searched for English peer-reviewed publications that were published from 1 January 2005 (year of publication of the Factor Seven for Acute Hemorrhagic Stroke phase II trials (FAST II)¹⁶) to 30 June 2021. Randomised trials that compared haemostatic agents with placebo for the patients with ICH with high risk for haematoma expansion predicted by CT signs were identified. The following terms were used for the database search: 'intracranial hemorrhages', 'hemorrhages', 'cerebral brain hemorrhage', 'tranexamic acid', 't-AMCHA', 'AMCA', 'anvitoff', 'cyklokapron', 'spotof', 'transamin', 'mchafibrin', 'exacyl', 'Recombinant activated coagulation factor VII', 'rFVIIa', 'factor vii', 'factor seven', 'coagulation factor', 'aminocaproic acid', '6-Aminohexanoic Acid', 'epsilon-Aminocaproic Acid', '6-Aminocaproic Acid', 'CT', 'computed tomography', 'spot', 'black hole', 'blend'. Related reviews, clinical trial databases and the reference lists of all retrieved articles were also searched manually to identify relevant studies.

Selection criteria

According to the objective of this analysis, only randomised trials that reported original data on haematoma expansion incidence after any haemostatic agents use in high-risk patients with ICH predicted by positive signs on CT were considered for inclusion in the meta-analysis, and the needed data could be from overall analysis, subgroup analysis or post hoc analyses. All non-RCTs, including observational studies, reviews, editorials, letters and case reports, were excluded. The study subjects were restricted to adult patients with spontaneous ICH. In addition, haematoma expansion should be defined as the presence of any ICH growth at 24 hours (>33% or >6 mL from base-line volume).

Primary and secondary outcomes

The primary outcome was early haematoma expansion, defined as the presence of ICH growth measured at 24 hours (>33% or >6 mL from baseline volume). The secondary outcomes were poor functional outcome defined by a modified Rankin Scale (mRS) between 4 and 6 at 90±7 days and death at 90 days.

Data extraction and quality assessment

Two physicians independently extracted data from identified publications based on the inclusion criteria. Disagreements were resolved through the discussion among all authors until a consensus was reached. Methods specified in the Cochrane Handbook of Systematic Reviews were adopted in this study for the objective assessment of the included trials.¹⁷ Data on the total number of patients treated, duration of follow-up and specifics of the intervention and control groups were extracted from publications. The occurrence of the following events was extracted for individual trials and analysed separately for the haemostatic therapy group and the control group: number of patients with haematoma expansion, number of patients with an mRS of 4–6 (indicating reasonably poor functional outcome at 90 days) and number of deceased patients at 90 days. If the above data were not available, the unadjusted ORs, as the indicators of the efficacy, were extracted, as an alternative. Characteristic data were also retrieved. To assess the reliability of the pooled results, risks of bias for each article and the overall study were assessed and reported according to the recommendations of the Cochrane Handbook for Systematic Reviews of Intervention using Cochrane collaboration's tool.¹⁷

Data synthesis and analysis

To combine the data from each study, the common-effect model with an inverse-variance (CE IV) method was used to calculate a summary estimate across all included studies. The OR estimates and associated 95% CIs for each of the endpoints were calculated. If only the subgroup of the trial met the inclusion criteria, analysis with and without the overall population from that trial would be carried out separately, as a part of sensitivity analysis. Subgroup analysis was prespecified based on the CT signs, types of haemostatic agents, following the methods outlined by CE IV for each outcome. Between-study and betweensubgroup heterogeneities were evaluated by calculating the I² statistic and the Cochrane Q (χ^2) statistic, with a p value of 0.10 set for significance of the test of heterogeneity. The results of sensitivity analysis were showed graphically, demonstrating the influence of each study on the overall meta-analysis summary estimate. Funnel plots graphically showing the logarithm of the SE and the effect size to evaluate publication bias was also created. All tests were two-tailed with a p value of 0.05 considered significant. All analyses were performed using the Review Manager V.5.4 (The Nordic Cochrane Center, The Cochrane Collaboration, 2020, Copenhagen, Denmark) and Stata V.16.0 (StataCorp LLC, College Station, 2019, Texas, USA) software.

RESULTS

Description of study characteristics

The database search identified 2406 publications with one additional report from other sources (online supplemental 1). A total of four randomised trials with 2666 patients were eligible for the meta-analysis.⁶ ¹²⁻¹⁴ Of the four trials, one enrolled both supratentorial and infratentorial patients with ICH⁶ and three enrolled only supratentorial patients with ICH.¹²⁻¹⁴ Two trials included patients with a positive spot sign only^{13 14} and one trial selected patients with at least one of the three positive CT signs (positive spot sign, black hole sign or blend sign).¹² In another trial, CT signs were not considered as inclusion criteria,⁶ for which, the original data needed for the current analysis were extracted from the subgroup analysis and post hoc analysis.¹⁸ Tranexamic acid was used in three trials^{6 12 14} and recombinant activated coagulation factor VII (rFVIIa) in one trial.¹³ The control group in all trials received saline as the placebo. The average duration of follow-up was 90 days. The mean duration from

able 1 Characteristics of the studies included in the systematic review and meta-analysis					
Variable	TRAIGE	STOP-AUST	SPOTLIGHT and STOP-IT	TICH-2	
Start time, y	2015	2012	2010	2013	
Publication time, y	2021	2020	2019	2018	
Location	10 centres in China	13 centres in Australia	12 centres in Canada	123 centres in 12 countries	
Study type	mRCT	mRCT	mRCT	mRCT	
Participant	Supratentorial ICH	Supratentorial ICH	Supratentorial ICH	ICH	
CT signs	Spot sign, black hole sign, or blend sign	Spot sign only	Spot sign only	Data on CT sign were unavailable for subjects included in the overall analysis; spot sign in subgroup analysis; black hole sign and blend sign in post hoc analyses	
Time (hour)	<6	<4.5	<6.5	<8	
Number of patients in treatment group/ total for primary analysis	89/172	50/100	32/69	1161/2325 in main overall analysis; 24/56 in spot sign subgroup; 411 in black hole sign subgroup; 364 in blend sign subgroup*	
Age, mean±SD, y	55.9±11.6	71 (IQR 57–79)	70.7±13.7 66.7±12.4†	68.9±13.8	
Male, n (%)	124 (72.5)	62 (62.0)	35 (50.7)	1301 (56.0)	
Baseline NIHSS, median (IQR)	11.0 (7.0–15.0)	NA	16.0 (11.0–18.5) 16.0 (13.0–20.0)	13.1±7.5 12.9±7.5	
Hypertension, n (%)	114 (66.7)	69 (69.0)	49 (71.0)	1421 (61.1)	
ICH volume, mean±SD, mL	23.7±18.7	14.6 (IQR 7.9–32.7)	16.3 (9.6–19.2) 20.4 (8.6–32.6)	24.0±27.2	
Intraventricular haemorrhage, n (%)	33 (19.3)	22 (22.0)	28 (40.6)	745 (32.0)	
Spot sign, n (%)	94 (55.0)	100 (100.0)	69 (100.0)	56 (2.4)	
Blend sign, n (%)	47 (27.5)	NA	NA	411 (17.7)	
Black hole sign, n (%)	107 (62.6)	NA	NA	364 (15.7)	
Onset to treatment, median (IQR), hour	290 (185–370)	150 (118–203)	178 (138–197)	246 (NA)	
Randomisation	Randomised 1:1, double-blind, placebo-controlled	Randomised 1:1, double-blind, placebo- controlled	Randomised 1:1, double-blind, placebo- controlled	Randomised 1:1, double- blind, placebo-controlled	
Intervention	Tranexamic acid: 1 g in 100 mL 0.9% NaCl over 10 min followed by 1 g in 250 mL 0.9% NaCl infusion over 8 hours	Tranexamic acid: 1 g in 100 mL 0.9% NaCl over 10 min followed by 1 g in 500 mL 0.9% NaCl infusion over 8 hours	rFVIIa: 80 µg/kg bolus	Tranexamic acid: 1 g in 100 mL 0.9% NaCl over 10 min followed by 1 g in 250 mL 0.9% NaCl infusion over 8 hours	
Control	Placebo: saline	Placebo: saline	Placebo: saline	Placebo: saline	
ITT	Yes	Yes	Yes	Yes	
Primary outcome	HE 24 hours	HE 24 hours	HE 24 hours	mRS 90 days	
Secondary outcome‡	mRS 90 days, death	mRS 90 days, death	mRS 90 days, death	HE 24 hours, death	
Follow-up	90 days	90 days	90 days	90 days	

Stroke Vasc Neurol: first published as 10.1136/svn-2021-000941 on 1 April 2021. Downloaded from http://svn.bmj.com/ on June 22, 2025 by guest. Protected by copyright.

Table 1	Continued				
Variable		TRAIGE	STOP-AUST	SPOTLIGHT and STOP-IT	TICH-2

Haemostatic therapy for preventing haematoma expansion.

*Numbers of subjects in the treatment group and the control group in the subgroups of TICH-2 were unavailable.

†a | b indicated data for the treatment group and the control group when data for total population were unavailable.

‡Details of other secondary outcomes of each included trial were listed in online supplemental 2.

HE, haematoma expansion; ICH, intracerebral haemorrhage; ITT, intention-to-treat analysis; mRCT, multicenter randomised controlled trial; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; rFVIIa, Recombinant factor VIIa;SPOTLIGHT, The"Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy; STOP-AUST, the Spot sign and Tranexamic acid On Preventing ICH growth—AUStralasia Trial; STOP-IT, The Spot Sign for Predicting and Treating ICH Growth Study; TICH-2, Tranexamic acid for hyperacute primary intracerebral hemorrhage; TRAIGE, Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign.

the onset to treatment was 150 to 290 mins and the ICH volume at baseline was 14.6~24.0 mL. The risk of bias assessment for randomised clinical trials is presented in online supplemental 2 and all studies included in this review presented a low risk of bias and high quality. All trials adopted the randomised, double-blind, placebo-controlled design and intention-to-treat analysis for the primary analysis. More details of the design and characteristics of the included trials are provided in table 1 and online supplemental file 3.

Haemostatic therapy reduced the rate of haematoma expansion at a marginally significant level, compared with placebo (27.4 vs 40.0% in the control group; OR 0.84; 95% CI 0.70 to 1.00; p=0.051), and the result had similar trends but with less significance when patients from Tranexamic acid for hyperacute primary intracerebral hemorrhage (TICH-2) were excluded⁶ (41.5 vs 45.0% in the control group; OR 0.87; 95% CI 0.57 to 1.34; p=0.52) (figure 1A). For patients with the spot sign, the rate of haematoma expansion was similar between the haemostatic therapy group and the control group (OR 0.98; 95% CI 0.60 to 1.59; p=0.93). For patients with the blend sign, the rate of haematoma expansion was marginally lower in the haemostatic therapy group with no statistical significance (OR 0.75; 95% CI 0.50 to 1.11; p=0.15). For patients with the black hole sign, a significant reduction of haematoma expansion was seen in the haemostatic therapy group (OR 0.61; 95% CI 0.39 to 0.94; p=0.03). The subgroup analysis on different haemostatic agents revealed no significant difference in the rate of haematoma expansion. Notably, there was no significant heterogeneity across the four studies and subgroups, except for the subgroup with the black hole sign (figure 1B,C).

Haemostatic therapy and clinical outcome

A total of four studies were included for the analysis of the clinical outcome. There was no significant heterogeneity between the four studies and their subgroups. When all patients were analysed, haemostatic therapy did not reduce the rate of the poor functional outcome when compared with placebo (53.3 vs 53.3% in the control group; OR 1.00; 95% CI 0.86 to 1.17; p=0.96 and 45.8 vs 46.3% in the control group; OR 0.94; 95% CI 0.60 to 1.47; p=0.78) whether TICH-2 (figure 2A) was included or not. The results in all subgroup analyses were generally consistent with the main analysis (figure 2B,C). No benefit was seen in reducing 90-day mortality after haemostatic therapy (figure 3A–C) in the main or subgroup analysis.

Sensitivity analyses and risk of bias

Sensitivity analysis for the rate of each endpoint showed that the overall effect of haemostatic therapy was consistent with the overall estimate from all studies excluding the TICH-2 study. Sensitivity analysis by sequentially dropping individual trials and then evaluating the overall outcomes failed to identify any of the individual trials that influenced the outcomes to any significant extent. Fixed-effects analyses showed a consistent trend for haemostatic therapy in all sensitivity analyses for the rate of haematoma expansion (online supplemental 4). There was also no significant publication bias detected with the examination of funnel plots for the outcome of haematoma expansion or with Egger's regression test (online supplemental 5).

DISCUSSION

Our meta-analysis of meticulously performed RCTs that compared haemostatic therapy with placebo in patients with spontaneous ICH predicted by CT signs showed a potential nonstatistically significant benefit of reducing early haematoma expansion with haemostatic therapy. Haemostatic therapy did not lower the 90-day risk of poor functional outcome and all-cause mortality. However, in patients with the black hole sign, there was a statistically significant reduction of haematoma expansion with haemostatic therapy, a benefit not seen in subgroups with other CT signs. This is the first meta-analysis of published trials of high-quality and low bias risk that evaluates the effectiveness of haemostatic therapy for spontaneous ICH predicted by CT signs.

Haemostatic therapy for spontaneous ICH without CT signs

The rFVIIa was a rapid procoagulant developed for haemophilia-related haemorrhage. In previous trials (FAST-2,¹⁶ FAST-3¹⁹), FVIIa reduced ICH expansion by about 50% compared with placebo but did not improve clinical outcomes.¹⁹ Tranexamic acid for patients with

А

All Studies

TRAIGE

TICH-2

TRAIGE

В

STOP-AUST TRAIGE

TRAIGE TICH-2

Blend sign

TRAIGE

TICH-2

С

rFVIIa

STOP-AUST

TRAIGE



Figure 1 Haematoma expansion for haemostatic therapy and placebo. (A) Analysis of all trials with and without TICH-2. (B) Subgroup analysis of CT signs. (C) Subgroup analysis of haemostatic agents. rFVIIa, recombinant activated coagulation factor VII; STOP-AUST, the Spot sign and Tranexamic acid On Preventing ICH growth-AUStralasia Trial; SPOTLIGHT, The "Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy; STOP-IT, The Spot Sign for Predicting and Treating ICH Growth Study; TICH-2, Tranexamic acid for hyperacute primary intracerebral hemorrhage; TRAIGE, Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign.

ICH was first tested in Malaysian trial $(n=30)^{20}$ and TICH trial (n=24),²¹ which revealed a reduction of ICH expansion. Following that, a pragmatic phase III prospective double-blind randomised placebo-controlled trial, TICH-2⁶ enrolled 2325 patients with ICH who received either tranexamic acid or placebo within 8 hours of onset. In the TICH-2 trial, tranexamic acid did not show any benefit in 90-day functional outcome when compared with placebo (adjusted OR 0.88; 95% CI 0.76 to 1.03; p=0.11), despite a reduction in early deaths and serious adverse events.

However, a potential benefit of reducing haematoma expansion was seen in a smaller proportion of patients treated with the tranexamic acid (265 (25%)/1054 vs)placebo 304 (29%)/1058) with an OR of 0.80 (95% CI 0.66 to 0.98; p=0.03). The absolute effect on reducing haematoma growth was modest (1mL). Overall, haemostatic therapy had a slight benefit in reducing haematoma growth but did not significantly improve the functional outcome in patients with ICH without any CT signs.



В

5	Odds Ratio	%
T signs and study	(95% CI)	Weight
POT SIGN		
POTLIGHT STOP-IT	0.83 (0.29, 2.32)	21.03
TOP-AUST	0.67 (0.30, 1.47)	36.15
RAIGE	2.01 (0.78, 5.14)	25.35
CH-2	1.16 (0.37, 3.57)	17.48
bgroup, IV (I ² = 8.9%, p = 0.349)	1.02 (0.63, 1.63)	100.00
LACK HOLE SIGN		
RAIGE	1.68 (0.52, 5.40)	18.99
CH-2	0.72 (0.41, 1.27)	81.01
bgroup, IV (I ² = 39.0%, p = 0.200)	0.85 (0.51, 1.41)	100.00
LEND SIGN		
RAIGE	• 1.51 (0.66, 3.46)	33.22
CH-2 •	0.83 (0.46, 1.48)	66.78
ubgroup, IV (I ² = 25.7%, p = 0.246)	1.01 (0.63, 1.63)	100.00
eterogeneity between groups: p = 0.842		
	I	
²⁵ Favors intervention ¹ Fav	vors control 4	



Figure 2 Poor functional outcome (mRS>3) for haemostatic therapy and placebo. (A) Analysis of all trials with and without TICH-2. (B) Subgroup analysis of CT signs. (C) Subgroup analysis of haemostatic agents. rFVIIa,recombinant activated coagulation factor VII; STOP-AUST,the Spot sign and Tranexamic acid On Preventing ICH growth—AUStralasia Trial; SPOTLIGHT,The"Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy; STOP-IT,The Spot Sign for Predicting and Treating ICH Growth Study; TICH-2,Tranexamic acid for hyperacute primary intracerebral hemorrhage; TRAIGE, Tranexamic Acid for Acute ICH GrowthprEdicted by Spot Sign.

Haemostatic therapy for spontaneous ICH with CT signs

Some researchers believe that haemostatic therapy is more appropriate for patients at high risk for ICH growth, such as patients presented early and with early CT signs predicting haematoma growth. For this reason, high-risk patients with ICH with image biomarkers, such as the spot, black hole and blend signs on CT, were identified as candidates for haemostatic therapy in recent randomised trials. The Spot Sign for Predicting and Treating ICH Growth Study (STOP-IT) and the "Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT), published in 2019, were phase 2 trials using the spot sign as a selection criterion.¹³ These trials recruited 69 patients with ICH over 6 years to receive either rFVIIa or placebo, with a median time from CT scan to treatment of 79 min (IQR 61–99) in the rFVIIa group. Both trials did not show any significant



²⁵ Favors intervention ¹ Favors control

Figure 3 All-cause mortality for haemostatic therapy and placebo. (A) Analysis of all trials with and without TICH-2. (B) Subgroup analysis of CT signs. (C) Subgroup analysis of haemostatic agents. rFVIIa,recombinant activated coagulation factor VII; STOP-AUST,the Spot sign and Tranexamic acid On Preventing ICH growth—AUStralasia Trial; SPOTLIGHT,The"Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy; STOP-IT,The Spot Sign for Predicting and Treating ICH Growth Study; TICH-2,Tranexamic acid for hyperacute primary intracerebral hemorrhage; TRAIGE, Tranexamic Acid for Acute ICH GrowthprEdicted by Spot Sign.

reductions of haematoma growth with rFVIIa (13 (41%)/vs 16 (43%)/37; p=0.83) or severe disability (9 (30%)/30 vs 13 (38%)/34; p=0.60).

The Spot sign and Tranexamic acid On Preventing ICH growth—AUStralasia Trial (STOP-AUST), published in 2020, was a phase 2 trial with 100 patients with ICH with the spot sign randomised to receive tranexamic acid (50) or placebo (50).¹⁴ The study did not show any benefit of tranexamic acid in reducing haematoma growth (OR

0.72; 95% CI 0.32 to 1.59; p=0.41), although the treatment is proven to be safe.

TRAIGE was a phase 2 trial that compared tranexamic acid with placebo in patients with ICH with the spot, blend or black hole signs.¹² All qualified patients had an noncontrast computed tomography (NCCT) or contrast-enhanced CT within 6 hours from the onset. This latest study found no benefit of tranexamic acid on reducing haematoma growth (OR 0.96; 95% CI 0.52 to 1.77; p=0.89)

or improving clinical outcomes with a generalised OR of 1.11 (95% CI 0.65 to 1.90; p=0.70), which is consistent with the previous studies.

Furthermore, in 249 patients enrolled in the TICH-2 trial, 56 patients with a positive spot sign were randomised to receive tranexamic acid (24) or placebo (32). The trial found a poor treatment effect of tranexamic acid in the subgroup analysis. In the post hoc analysis in the same study¹⁸ for the purpose of defining the role of the NCCT signs as predictors of haematoma expansion and poor functional outcome, blend sign, black hole sign and hypodensities were found to be predictive of haematoma expansion. Black hole sign, hypodensities and island signs predicted a poor functional outcome. The study did not show any significant correlation between the presence of signs and the benefit of tranexamic acid in reducing haematoma expansion. NCCT signs do not indicate a better response to tranexamic acid regarding the clinical outcome. In summary, studies on patients susceptible to haemorrhage expansion predicted by CT signs, especially the spot sign, showed that haemostatic therapy did not significantly prevent the haematoma growth or improve the outcome.

Future direction

This meta-analysis showed that haemostatic therapy might have the benefit of reducing early haematoma expansion in selected patients with ICH. It has been reported by a prior systematic review²² that haemostatic therapy does not increase the occurrence of thrombotic events. However, no significant improvement in prognosis or reduction in mortality was observed with haemostatic therapy in patients with ICH with or without CT signs. There are several possible explanations. First, modest absolute volume reduction in haematoma may not be sufficient to show clinical benefit.^{6 14} Second, the previous studies⁶ showed some other uncertainties that might impact the outcome. Haemostatic therapy could modestly reduce haematoma expansion but not enough to alter the pathophysiological process. For example, haemostatic therapy could not change perihaematomal brain oedema²³ and other complications, similar to the limitations of surgical intervention for ICH.^{24 25} However, these unresolved clinical problems may have a bigger impact on the final prognosis of patients with ICH.²³ Predictive CT signs used in these studies were proved to be valuable in predicting haematoma expansion and poor prognosis,²⁶ but the underlying pathological mechanisms remain unclear. It appears that different CT signs may have different predictive roles in evaluating the therapeutic effects of the haemostatic therapy. It is time to evaluate different predictive CT signs in those subgroups that showed potentially improved outcome. In the post hoc analysis of Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-2),²⁷ ultraearly blood pressure (BP) reduction ≤2 hours could reduce haematoma growth and further

improve functional outcome. Subgroup analyses from the TICH-2, STOP-AUST and TRAIGE all found that earlier treatment (within 2–3 hours) seemed to show more benefit. The proposed time window could also be used for haemostatic therapy in future research. More trials using tranexamic acid to treat ICH in the early time window are already ongoing (EudraCT 2012-005594-30 and ClinicalTrials.gov NCT03385928). There was speculation that haemostatic therapy might be similar to intravenous thrombolysis for ischaemic stroke, namely, earlier cessation of haematoma expansion might stop the trend of a cascade of deterioration.²⁸

Even though the results of these studies do not support the haemostatic therapy at present, further studies on better-defined subgroups of ICH patients are warranted. Tranexamic acid has certain advantages for this role. It is low-cost, widely used, safe and suitable for promotion on a global scale. However, recruitment of patients with high-risk ICH is difficult because of the strict selection criteria and difficulty of obtaining emergency CT angiography routinely. Global collaboration may be the solution to the re-evaluation of tranexamic acid with a trial in a highly selective ICH population.

Limitation

The analysis on the overall population and subgroup population of TICH-2 were included in the current analysis, where the overall population also included patients without CT signs. To reduce the effect of bias of population differences, analysis with and without the overall population of TICH-2 was carried out separately as part of sensitivity analysis. However, the CI of primary analysis when patients from TICH-2 were excluded was significantly wider (p=0.52) than with TICH-2 included (p=0.051). Perhaps the sample size of the TICH-2 study is the main reason that TICH-2 may be driving much of the potential significance for reducing rate of haematoma expansion. The Factor VII phase IIb and phase III trials (FAST III) were representative researches on the evaluation of the effect of Factor VII on the prevention of haemorrhage growth in all ICH patients and the original data from FAST III on a subgroup of high-risk patients with ICH predicted by positive signs on CT could not be extracted from published reports, therefore, we could not get the original data. For these reasons, we excluded FAST III from the current analysis. Furthermore, subgroup analysis for each CT sign was performed to determine the difference in efficacy for patients with different CT signs. Since the inclusion of the RCT subgroup would lead to the decline of the overall study quality, the quality of subgroup analysis based on CT signs in this study was only equivalent to the level of a meta-analysis of cohort study. In addition, there were some differences in the protocols across the studies. For instance, the onset-to-randomisation time limits ranged from 4.5 to 8 hours, and different

Open access

haemostatic agents were used. These differences may lead to differences in the results. Sensitivity analysis was carried out to test the interstudy bias, but no positive interstudy bias that affected the results was found. Moreover, there were obvious differences in the sample size across studies. The sample size of the TICH-2 study was significantly larger than that of other studies. However, there was no significant publication bias found.

CONCLUSIONS

Haemostatic therapy may reduce haematoma expansion at a marginally significant level but could not lower the risk of 90-day poor functional outcome and all-cause mortality in high-risk patients with ICH with predictive CT signs. Although the data did not support the wide use of haemostatic therapy clinically, it may have provided directions in future research of treating patients with ICH.

Author affiliations

¹Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

²China National Clinical Research Center for Neurological Diseases, Beijing, China ³Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

⁴Department of Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Acknowledgements The authors thank Lina Zheng, Jiahui Zhao, Ying Tan, Yaozhi Chen and other study coordinators for their meticulous work and are grateful for the participation and engagement of all the subjects and investigators of the TRAIGE trial and this Meta-analysis.

Contributors Study concept and design: LL, SS and WW. Drafting of the manuscript: XN and JL. Statistical analysis: QZ and HG. Study supervision and organisation of the project: DL, HS and WD. Revision of the manuscript: YP, ZY and MW.

Funding The study is funded by grants from the Beijing Science and Technology Commission (D141100000114002), National Natural Science Foundation of China (81820108012, 81971614), National Key R&D Program of China (2016YFC1307301, 2018YFC1312402).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed. Data availability statement Data are available upon reasonable request. Data in this article are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Ximing Nie http://orcid.org/0000-0002-8380-4076 Jingyi Liu http://orcid.org/0000-0001-7360-0267 Dacheng Liu http://orcid.org/0000-0003-3786-9255 Wanying Duan http://orcid.org/0000-0003-3527-9454 Hongqiu Gu http://orcid.org/0000-0003-1608-1856 Liping Liu http://orcid.org/0000-0003-2943-055X

REFERENCES

1 Collaborators GBDRF, GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. *Lancet* 2018;392:1923–94.

- 2 Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American heart Association/American stroke association. Stroke 2015;46:2032–60.
- 3 Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. *Drugs* 1999;57:1005–32.
- 4 Delcourt C, Huang Y, Arima H, et al. Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. *Neurology* 2012;79:314–9.
- 5 Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. *Neurology* 2006;66:1175–81.
- 6 Sprigg N, Flaherty K, Appleton JP, et al. Tranexamic acid for hyperacute primary intracerebral haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet 2018;391:2107–15.
- 7 Morotti A, Arba F, Boulouis G, *et al.* Noncontrast CT markers of intracerebral hemorrhage expansion and poor outcome: a meta-analysis. *Neurology* 2020;95:632–43.
- 8 Thompson AL, Kosior JC, Gladstone DJ, et al. Defining the CT angiography 'spot sign' in primary intracerebral hemorrhage. Can J Neurol Sci 2009;36:456–61.
- 9 Koculym A, Huynh TJ, Jakubovic R, et al. Ct perfusion spot sign improves sensitivity for prediction of outcome compared with cta and postcontrast CT. AJNR Am J Neuroradiol 2013;34:965–70.
- 10 Li Q, Zhang G, Xiong X, et al. Black hole sign: novel imaging marker that predicts hematoma growth in patients with intracerebral hemorrhage. Stroke 2016;47:1777–81.
- 11 Li Q, Zhang G, Huang Y-J, et al. Blend sign on computed tomography: novel and reliable predictor for early hematoma growth in patients with intracerebral hemorrhage. Stroke 2015;46:2119–23.
- 12 Liu L, Wang Y, Meng X, *et al.* Tranexamic acid for acute intracerebral hemorrhage growth predicted by spot sign trial: rationale and design. *Int J Stroke* 2017;12:326–31.
- 13 Gladstone DJ, Aviv RI, Demchuk AM, et al. Effect of recombinant activated coagulation factor VII on hemorrhage expansion among patients with spot Sign-Positive acute intracerebral hemorrhage: the spotlight and STOP-IT randomized clinical trials. *JAMA Neurol* 2019. doi:10.1001/jamaneurol.2019.2636. [Epub ahead of print: 19 Aug 2019].
- 14 Meretoja A, Yassi N, Wu TY, *et al.* Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial. *Lancet Neurol* 2020;19:980–7.
- 15 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8:336–41.
- 16 Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777–85.
- 17 Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for systematic reviews of interventions. *Cochrane Database Syst Rev* 2019;10:ED000142.
- 18 Law ZK, Ali A, Krishnan K, et al. Noncontrast computed tomography signs as predictors of hematoma expansion, clinical outcome, and response to tranexamic acid in acute intracerebral hemorrhage. Stroke 2020;51:121–8.
- 19 Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008;358:2127–37.
- 20 Arumugam A, A Rahman NA, Theophilus SC, et al. Tranexamic acid as antifibrinolytic agent in non traumatic intracerebral hemorrhages. Malays J Med Sci 2015;22:62–71.
- 21 Sprigg N, Renton CJ, Dineen RA, et al. Tranexamic acid for spontaneous intracerebral hemorrhage: a randomized controlled pilot trial (ISRCTN50867461). J Stroke Cerebrovasc Dis 2014;23:1312–8.
- 22 Hu W, Xin Y, Chen X, *et al*. Tranexamic acid in cerebral hemorrhage: a meta-analysis and systematic review. *CNS Drugs* 2019;33:327–36.
- 23 Selim M, Norton C. Perihematomal edema: implications for intracerebral hemorrhage research and therapeutic advances. *J Neurosci Res* 2020;98:212–8.

9

- 24 Sattur MG, Spiotta AM. Commentary: efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomized, controlled, open-label, blinded endpoint phase 3 trial. *Neurosurgery* 2020;86:E444–6.
- 25 Engrand N, Mazighi M, Le Guerinel C, *et al.* Surgery for intracerebral haemorrhage. *Lancet* 2019;394:e20.
- 26 Sporns PB, Schwake M, Kemmling A, et al. Comparison of spot sign, blend sign and black hole sign for outcome

prediction in patients with intracerebral hemorrhage. *J Stroke* 2017;19:333–9.

- 27 Li Q, Warren AD, Qureshi AI, *et al.* Ultra-Early blood pressure reduction attenuates hematoma growth and improves outcome in intracerebral hemorrhage. *Ann Neurol* 2020;88:388–95.
- 28 Law ZK, Meretoja A, Engelter ST, et al. Treatment of intracerebral haemorrhage with tranexamic acid - A review of current evidence and ongoing trials. *Eur Stroke J* 2017;2:13–22.